The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 5, 2006, Pages 699-702

  Bruynzeel, Anna M E ^a   Mul, Paula P N ^a   Berkhof, Johannes ^a   Bast, Aalt ^b   Niessen, Hans W M ^a,c   Van Der Vijgh, Wim J F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Cardiotoxicity; Doxorubicin; MonoHER; Monohydroxyethylrutoside; Protection

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; FLAVONOID; MONOXERUTIN; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CHRONOPHARMACOLOGY; CHRONOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; HEART; HEART MUSCLE CELL; HEART PROTECTION; MALE; MICROSCOPY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ACUTE TOXICITY TESTS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HYDROXYETHYLRUTOSIDE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, VIDEO; MYOCYTES, CARDIAC; TIME FACTORS; VACUOLES;

EID: 33746732921     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0206-9     Document Type: Article

References (32)

1. Hrdina R, Gersl V, Klimtova I, Simunek T, Machackova J, Adamcova M (2000) Anthracycline-induced cardiotoxicity. Acta Medica 43(3):75-82
2. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA (1973) A Clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302-314
3. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339(13):900-904
4. Horenstein MS, Vander Heide RS, L'Ecuyer TJ (2000) Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab 71:436-444
5. Xu MF, Tang PL, Oian ZM, Ashraf M (2001) Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci 68(8):889-901
6. Iarussi D, Indolfi P, Galderisi M, Bossone E (2000) Cardiac toxicity after anthracycline chemotherapy in childhood. Herz 25(7):676-688
7. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229
8. Myers C (1998) The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 25:10-14
9. Liu X, Chen Z, Chua CC, Ma YS, Youngberg GA, Hamdy R, Chua BHL (2002) Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 283(1):H254-H263
10. Oliveira PJ, Bjork JA, Santos MS, Leino RL, Froberg MK, Moreno AJ, Wallance KB (2004) Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol 200(2):159-168
11. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332
12. Swain SM, Vici P (2004) The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 130:1-7
13. Billingham ME, Mason JW, Bristow MR, Daniels JR (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62(6):865-872
14. Rosenoff SH, Olson HM, Young DM, Bostick F, Young RC (1975) Adriamycin-induced cardiac damage in the mouse: a small animal model of cardiotoxicity. J Natl Cancer Inst 55(1):191-194
15. Haenen GRMM, Jansen FP, Bast A (1993) The antioxidant properties of five O- (beta-hydroxyethyl) rutosides of the flavonoid mixture Venoruton. Phlebology 1(Suppl):10-17
16. Van Acker SABE, Towart R, Husken BCP, de Jong J, van der Vijgh WJF, Bast A (1993) The protective effect of Venoruton and its constituents on acute doxorubicin-induced cardiotoxicity. Phlebology Suppl 1:31-32
17. Van Acker FAA, Van Acker SABE, Kramer K, Haenen GRMM, Bast A, Van der Vijgh WJF (2000) 7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week. Clin Cancer Res 6:1337-1341
18. Van Acker FAA, Hulshof JW, Haenen GRMM, Menge WMPB, Van der Vijgh WJF, Bast A (2001) New synthetic flavonoids as potent protectors against doxorubicin-induced cardiotoxicity. Free Radic Biol Med 31:31-37
19. Van Acker SABE, Boven E, Kuiper K, Van den Berg DJ, Grimbergen JA, Kramer K, Bast A, Van der Vijgh WJF (1997) Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res 3(10):1747-1754
20. Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents. Drug Safety 22(4):263-302
21. Wojtacki J, Lewicka-Nowak E, Lesniewski-Kmak K (2000) Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention - review of literature. Med Sci Monit 6(2):411-420
22. Brinkhuis M, Meijer GA, Belien JA, van Diest PJ, Baak JP (1995) Volume-weighted mean nuclear volume and nuclear area in advanced ovarian carcinoma. An investigation of sampling methods, sample size and reproducibility. Anal Quant Cytol Histol 17(4):284-290
23. Van Acker SABE, Kramer K, Voest EE, Grimbergen JA, Zhang J, van der Vijgh WJF, Bast A (1996) Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. Cancer Chemother Pharmacol 38:95-101
24. Abou El Hassan MAI, Rabelink MJWE, Van der Vijgh WJF, Bast A, Hoeben RC (2003) A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (monoHER) in protecting against doxorubicininduced cardiotoxicity in vitro. Br J Cancer 89:2140-2146
25. Van Acker SABE, Kramer K, Grimbergen JA, van den Berg DJ, van der Vijgh WJF, Bast A (1995) Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity. Br J Pharmacol 115:1260-1264
26. Van der Vijgh WJF, Maessen PA, Pinedo HM (1990) Comparative metabolism and pharmacokinetics of doxorubicin and 4′-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice. Cancer Chemother Pharmacol 26:9-12
27. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ (1982) Reduction of doxorubicin cardiotoxicty by prolonged continuous intravenous infusion. Ann Intern Med 96(2):133-139
28. Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK, Kohler M, Brown BW Jr, Billingham ME (1983) Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 99(6):745-749
29. Abou El Hassan MAI, Kedde MA, Zwiers UTH, Torun E, Haenen GRMM, Bast A, Van der Vijgh WJF (2003) Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice. Cancer Chemother Pharmacol 52(5):371-376
30. Kremer LCM, van Dalen EC, Offringa M, Ottenkamp J, Voute PA (2001) Anthracyclin-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 19:191-196
31. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukaemia in childhood. N Engl J Med 324:808-815
32. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy L (2001) Cardiac toxicity 4 to 20 years after completing anthracyclin therapy. JAMA 266(12):1672-1677